Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Neurochem ; 140(5): 755-765, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28027400

RESUMO

Over 25 years ago it was first reported that intracellular chloride levels (Cl-in ) were higher in developing neurons than in maturity. This finding has had significant implications for understanding the excitability of developing networks and recognizing the underlying causes of hyperexcitability associated with disease and neural injury. While there is some evidence that intracellular sodium levels (Na+in ) change during the development of non-neural cells, it has largely been assumed that Na+in is the same in developing and mature neurons. Here, using the sodium indicator SBFI, we test this idea and find that Na+in is significantly higher in embryonic spinal motoneurons and interneurons than in maturity. We find that Na+in reaches ~ 60 mM in mid-embryonic development and is then reduced to ~ 30 mM in late embryonic development. By retrogradely labeling motoneurons with SBFI we can reliably follow Na+in levels in vitro for hours. Bursts of spiking activity, and blocking voltage-gated sodium channels did not influence observed motoneuron sodium levels. On the other hand, Na+in was reduced by blocking the Na+ -K+ -2Cl- cotransporter NKCC1, and was highly sensitive to changes in external Na+ and a blocker of the Na+ /K+ ATPase. Our findings suggest that the Na+ gradient is weaker in embryonic neuronal development and strengthens in maturity in a manner similar to that of Cl- .


Assuntos
Espaço Intracelular/metabolismo , Neurônios/metabolismo , Sódio/metabolismo , Medula Espinal/crescimento & desenvolvimento , Medula Espinal/metabolismo , Animais , Benzofuranos , Embrião de Galinha , Galinhas , Cloretos/metabolismo , Desenvolvimento Embrionário , Éteres Cíclicos , Interneurônios/metabolismo , Neurônios Motores/metabolismo , Técnicas de Patch-Clamp , ATPase Trocadora de Sódio-Potássio/metabolismo , Medula Espinal/embriologia
2.
J Neurosci ; 36(27): 7268-82, 2016 07 06.
Artigo em Inglês | MEDLINE | ID: mdl-27383600

RESUMO

UNLABELLED: Homeostatic plasticity mechanisms maintain cellular or network spiking activity within a physiologically functional range through compensatory changes in synaptic strength or intrinsic cellular excitability. Synaptic scaling is one form of homeostatic plasticity that is triggered after blockade of spiking or neurotransmission in which the strengths of all synaptic inputs to a cell are multiplicatively scaled upward or downward in a compensatory fashion. We have shown previously that synaptic upscaling could be triggered in chick embryo spinal motoneurons by complete blockade of spiking or GABAA receptor (GABAAR) activation for 2 d in vivo Here, we alter GABAAR activation in a more physiologically relevant manner by chronically adjusting presynaptic GABA release in vivo using nicotinic modulators or an mGluR2 agonist. Manipulating GABAAR activation in this way triggered scaling in a mechanistically similar manner to scaling induced by complete blockade of GABAARs. Remarkably, we find that altering action-potential (AP)-independent spontaneous release was able to fully account for the observed bidirectional scaling, whereas dramatic changes in spiking activity associated with spontaneous network activity had little effect on quantal amplitude. The reliance of scaling on an AP-independent process challenges the plasticity's relatedness to spiking in the living embryonic spinal network. Our findings have implications for the trigger and function of synaptic scaling and suggest that spontaneous release functions to regulate synaptic strength homeostatically in vivo SIGNIFICANCE STATEMENT: Homeostatic synaptic scaling is thought to prevent inappropriate levels of spiking activity through compensatory adjustments in the strength of synaptic inputs. Therefore, it is thought that perturbations in spike rate trigger scaling. Here, we find that dramatic changes in spiking activity in the embryonic spinal cord have little effect on synaptic scaling; conversely, alterations in GABAA receptor activation due to action-potential-independent GABA vesicle release can trigger scaling. The findings suggest that scaling in the living embryonic spinal cord functions to maintain synaptic strength and challenge the view that scaling acts to regulate spiking activity homeostatically. Finally, the results indicate that fetal exposure to drugs that influence GABA spontaneous release, such as nicotine, could profoundly affect synaptic maturation.


Assuntos
Rede Nervosa/fisiologia , Medula Espinal/citologia , Sinapses/fisiologia , Potenciais de Ação/efeitos dos fármacos , Potenciais de Ação/fisiologia , Fatores Etários , Anestésicos Locais/farmacologia , Animais , Anticonvulsivantes/farmacologia , Embrião de Galinha , Cloretos/metabolismo , Ciclopropanos/farmacologia , Feminino , Glicina/análogos & derivados , Glicina/farmacologia , Homeostase/fisiologia , Lidocaína/farmacologia , Masculino , Neurônios Motores/fisiologia , Movimento/efeitos dos fármacos , Neurotransmissores/farmacologia , Receptores de GABA-A/metabolismo , Potenciais Sinápticos/efeitos dos fármacos , Ácido gama-Aminobutírico/metabolismo
3.
PLoS One ; 9(4): e94559, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24733046

RESUMO

Synaptic scaling represents a process whereby the distribution of a cell's synaptic strengths are altered by a multiplicative scaling factor. Scaling is thought to be a compensatory response that homeostatically controls spiking activity levels in the cell or network. Previously, we observed GABAergic synaptic scaling in embryonic spinal motoneurons following in vivo blockade of either spiking activity or GABAA receptors (GABAARs). We had determined that activity blockade triggered upward GABAergic scaling through chloride accumulation, thus increasing the driving force for these currents. To determine whether chloride accumulation also underlies GABAergic scaling following GABAAR blockade we have developed a new technique. We expressed a genetically encoded chloride-indicator, Clomeleon, in the embryonic chick spinal cord, which provides a non-invasive fast measure of intracellular chloride. Using this technique we now show that chloride accumulation underlies GABAergic scaling following blockade of either spiking activity or the GABAAR. The finding that GABAAR blockade and activity blockade trigger scaling via a common mechanism supports our hypothesis that activity blockade reduces GABAAR activation, which triggers synaptic scaling. In addition, Clomeleon imaging demonstrated the time course and widespread nature of GABAergic scaling through chloride accumulation, as it was also observed in spinal interneurons. This suggests that homeostatic scaling via chloride accumulation is a common feature in many neuronal classes within the embryonic spinal cord and opens the possibility that this process may occur throughout the nervous system at early stages of development.


Assuntos
Antagonistas de Receptores de GABA-A/química , Interneurônios/fisiologia , Neurônios Motores/fisiologia , Receptores de GABA-A/fisiologia , Sinapses/fisiologia , Animais , Calibragem , Embrião de Galinha , Cloretos/química , Transferência Ressonante de Energia de Fluorescência , Homeostase , Plasticidade Neuronal , Piridazinas/química , Medula Espinal/citologia , Medula Espinal/embriologia , Transmissão Sináptica/fisiologia , Fatores de Tempo , Xantenos/química
4.
J Neurosci ; 33(16): 6791-9, 2013 Apr 17.
Artigo em Inglês | MEDLINE | ID: mdl-23595738

RESUMO

When spiking activity within a network is perturbed for hours to days, compensatory changes in synaptic strength are triggered that are thought to be important for the homeostatic maintenance of network or cellular spiking activity. In one form of this homeostatic plasticity, called synaptic scaling, all of a cell's AMPAergic miniature postsynaptic currents (mEPSCs) are increased or decreased by some scaling factor. Although synaptic scaling has been observed in a variety of systems, the mechanisms that underlie AMPAergic scaling have been controversial. Certain studies find that synaptic scaling is mediated by GluA2-lacking calcium receptors (CP-AMPARs), whereas others have found that scaling is mediated by GluA2-containing calcium-impermeable receptors (CI-AMPARs). Spontaneous network activity is observed in most developing circuits, and in the spinal cord this activity drives embryonic movements. Blocking spontaneous network activity in the chick embryo by infusing lidocaine in vivo triggers synaptic scaling in spinal motoneurons; here we show that AMPAergic scaling occurs through increases in mEPSC conductance that appear to be mediated by the insertion of GluA2-lacking AMPA receptors at the expense of GluA2-containing receptors. We have previously reported that in vivo blockade of GABAA transmission, at a developmental stage when GABA is excitatory, also triggered AMPAergic synaptic scaling. Here, we show that this form of AMPAergic scaling is also mediated by CP-AMPARs. These findings suggest that AMPAergic scaling triggered by blocking spiking activity or GABAA receptor transmission represents similar phenomena, supporting the idea that activity blockade triggers scaling by reducing GABAA transmission.


Assuntos
Regulação da Expressão Gênica no Desenvolvimento/fisiologia , Neurônios Motores/fisiologia , Receptores de AMPA/deficiência , Medula Espinal/citologia , Sinapses/fisiologia , Anestésicos Locais/farmacologia , Animais , Biofísica , Embrião de Galinha , Estimulação Elétrica , Antagonistas de Aminoácidos Excitatórios/farmacologia , Potenciais Pós-Sinápticos Excitadores/fisiologia , Antagonistas GABAérgicos/farmacologia , Lidocaína/farmacologia , Técnicas de Patch-Clamp , Piridazinas/farmacologia , Medula Espinal/embriologia , Medula Espinal/metabolismo , Sinapses/efeitos dos fármacos , Tetrodotoxina/farmacologia
5.
J Physiol ; 588(Pt 15): 2801-22, 2010 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-20547680

RESUMO

We report that bath application of 3 mum carbachol (CCh), a muscarinic acetylcholine receptor agonist, reduces evoked IPSC amplitude recorded from hilar mossy cells in the rat dentate gyrus through a presynaptic mechanism. While CCh has been shown to inhibit evoked IPSCs in other systems, this effect is intriguing in that it does not require inhibitory action of either presynaptic muscarinic receptors or presynaptic cannabinoid receptors. Previous work from our lab has shown that identical application of CCh produces an action potential-dependent increase in ambient GABA in this system; however, inhibition of evoked IPSCs produced by both 3 and 10 mum CCh is insensitive to the GABA(B) antagonist CGP52432. Therefore we hypothesized that CCh-mediated inhibition of evoked IPSCs might be produced by activity-dependent increases in ambient GABA and subsequent activation of presynaptic GABA(A) receptors. Consistent with that hypothesis, we report that CCh-mediated inhibition of evoked IPSCs appears to be well correlated with CCh-mediated facilitation of spontaneous IPSCs and that CCh does not affect GABA(B)-mediated IPSCs recorded in the presence of the GABA(A) receptor antagonist picrotoxin. Intriguingly, however, we found that bath application of the GAT-1 transport blocker NO-711 (1 mum) produces inhibition of evoked IPSCs that is reversed by CGP52432, and that lower doses of CCh produce inhibition with greater CGP52432 sensitivity. These observations, combined with subsequent work on multiple pulse depression, reveal that feedback inhibition of GABAergic afferents to hilar mossy cells is governed by a complex relationship between two distinct and activity-dependent mechanisms.


Assuntos
Potenciais de Ação/fisiologia , Vias Aferentes/fisiologia , Autorreceptores/metabolismo , Fibras Nervosas/fisiologia , Inibição Neural/fisiologia , Neurônios/fisiologia , Ácido gama-Aminobutírico/metabolismo , Animais , Células Cultivadas , Giro Denteado/fisiologia , Ratos , Ratos Sprague-Dawley
6.
Neuropharmacology ; 58(4-5): 712-21, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20045707

RESUMO

We report that bath application of the group I mGluR agonist (RS)-3,5-dihydroxyphenylglycine (DHPG) causes acute inhibition of evoked IPSCs recorded from hilar mossy cells, and that significant long-term depression (LTD) of synaptic transmission remains following washout of DHPG. Subsequent experiments using minimal stimulation techniques revealed that expression of both acute and long-term effects of DHPG are restricted to a subset of GABAergic afferents that are also sensitive to depolarization-induced suppression of inhibition (DSI). Experiments with a selective CB1 antagonist and with transgenic animals lacking CB1 receptors indicate that all effects of DHPG, like DSI, depend on activation of CB1 receptors. Further work with selective mGluR antagonists suggests a direct involvement of mGluR1 receptors. Interestingly, we also report that induction of LTD under our experimental conditions does not require prior direct somatic depolarization via the patch pipette and does not appear to depend critically on the level of activity in incoming GABAergic afferents. Collectively, these results represent the first characterization of mGluR-mediated and endocannabinoid-dependent LTD in the hilar region of the dentate gyrus. The dentate gyrus is thus one of relatively few areas where this mechanism has clearly been demonstrated to induce long-term modulation of inhibitory synaptic transmission.


Assuntos
Moduladores de Receptores de Canabinoides/fisiologia , Giro Denteado/fisiologia , Endocanabinoides , Depressão Sináptica de Longo Prazo/fisiologia , Receptores de Glutamato Metabotrópico/fisiologia , Animais , Moduladores de Receptores de Canabinoides/biossíntese , Moduladores de Receptores de Canabinoides/farmacologia , Giro Denteado/efeitos dos fármacos , Potenciais Pós-Sinápticos Inibidores/efeitos dos fármacos , Potenciais Pós-Sinápticos Inibidores/fisiologia , Depressão Sináptica de Longo Prazo/efeitos dos fármacos , Masculino , Metoxi-Hidroxifenilglicol/análogos & derivados , Metoxi-Hidroxifenilglicol/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Ratos , Ratos Sprague-Dawley , Receptor CB1 de Canabinoide/antagonistas & inibidores , Receptor CB1 de Canabinoide/fisiologia , Receptores de Glutamato Metabotrópico/agonistas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...